Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Lalezari · SciRah

Researcher profile · Semantic Scholar

S. Lalezari

Share profile

S. Lalezari — researcher profile on SciRah

h-index: 17
Works: 39
Citations: 800

Most-cited papers

Endothelial Function in Patients with Hyperthyroidism Before and After Treatment with Propranolol and Thiamazol
J. Burggraaf, S. Lalezari, J. Emeis, U. Vischer +3 more
2001Thyroid124 citations
Semantic Scholar
Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease.
A. Mager, S. Lalezari, Tamar Shohat, Y. Birnbaum +3 more
1999Circulation79 citations Open access
Semantic Scholar
Sympathovagal imbalance in hyperthyroidism.
J. Burggraaf, J. Tulen, S. Lalezari, R. Schoemaker +4 more
2001American Journal of Physiology. Endocrinology and Metabolism76 citations
Semantic Scholar
Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial
K. Saxena, S. Lalezari, J. Oldenburg, D. Tseneklidou-Stoeter +3 more
2016Haemophilia56 citations Open access
Semantic Scholar
BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies
A. Shah, T. Coyle, S. Lalezari, Kathelijn Fischer +4 more
2018Haemophilia41 citations Open access
Semantic Scholar
Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII
A. Shah, H. Delesen, S. Garger, S. Lalezari
2015Haemophilia39 citations
Semantic Scholar
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
S. Lalezari, U. Martinowitz, J. Windyga, M. Enriquez +3 more
2013Haemophilia39 citations Open access
Semantic Scholar
Allele-specific replication associated with aneuploidy in blood cells of patients with hematologic malignancies.
A. Korenstein-Ilan, A. Amiel, S. Lalezari, M. Lishner +1 more
2002Cancer Genetics and Cytogenetics35 citations
Semantic Scholar
Recombinant factor concentrates may increase inhibitor development: a single centre cohort study
Tzipora Strauss, A. Lubetsky, B. Ravid, D. Bashari +5 more
2011Haemophilia31 citations
Semantic Scholar
The potential role of emicizumab prophylaxis in severe von Willebrand disease.
A. Barg, E. Avishai, I. Budnik, Tamar Barazani Brutman +8 more
2020Blood Cells, Molecules & Diseases28 citations
Semantic Scholar
BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
S. Lalezari, M. Reding, I. Pabinger, P. Holme +6 more
2019Haemophilia27 citations Open access
Semantic Scholar
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
E. Santagostino, S. Lalezari, M. Reding, J. Ducore +4 more
2019Thrombosis Research26 citations Open access
Semantic Scholar
Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
R. Dardik, E. Avishai, S. Lalezari, A. Barg +6 more
2021International Journal of Molecular Sciences24 citations Open access
Semantic Scholar
Hepatitis C at the Israeli National Hemophilia Center
Y. Maor, D. Bashari, G. Kenet, S. Lalezari +6 more
2006Haemophilia22 citations
Semantic Scholar
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
M. Reding, I. Pabinger, P. Holme, L. Poulsen +7 more
2021Haemophilia20 citations Open access
Semantic Scholar
Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme
J. Oldenburg, J. Windyga, K. Hampton, S. Lalezari +3 more
2016Haemophilia20 citations Open access
Semantic Scholar
Trp207Gly in platelet glycoprotein Ibα is a novel mutation that disrupts the connection between the leucine‐rich repeat domain and the disulfide loop structure and causes Bernard–Soulier syndrome
N. Rosenberg, S. Lalezari, M. Landau, B. Shenkman +2 more
2007Journal of Thrombosis and Haemostasis17 citations Open access
Semantic Scholar
Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
R. Dardik, S. Janczar, S. Lalezari, E. Avishai +6 more
2023International Journal of Molecular Sciences13 citations Open access
Semantic Scholar
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
O. Cohen, S. Levy-Mendelovich, I. Budnik, N. Ludan +10 more
2023Research and Practice in Thrombosis and Haemostasis12 citations Open access
Semantic Scholar
Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
M. Reding, I. Pabinger, S. Lalezari, E. Santagostino +1 more
2020Haemophilia9 citations Open access
Semantic Scholar
Patient characteristics that influence efficacy of prophylaxis with rFVIII‐FS three times per week: a subgroup analysis of the LIPLONG study
S. Lalezari, A. Coppola, J. C. Lin, M. Enriquez +3 more
2014Haemophilia9 citations
Semantic Scholar
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
M. Reding, S. Lalezari, G. Kenet, G. Di Minno +8 more
2024Drugs in R&D7 citations Open access
Semantic Scholar
Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A
E. Santagostino, S. Lalezari, M. Reding, J. Ducore +4 more
2021Haemophilia7 citations Open access
Semantic Scholar
Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
S. Lalezari, A. Barg, R. Dardik, J. Luboshitz +3 more
2021TH Open6 citations Open access
Semantic Scholar
Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon.
G. Ben Haim, U. Manor, Sarit Appel, S. Lalezari +2 more
2017The Israel Medical Association journal : IMAJ6 citations
Semantic Scholar
Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)
U. Martinowitz, A. Lubetsky, E. Santagostino, G. Jotov +7 more
20126 citations
Semantic Scholar
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
A. Solms, S. Lalezari, Anita Shah, G. Kenet
2020Haemophilia5 citations Open access
Semantic Scholar
BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
J. Mahlangu, M. López-Fernández, E. Santagostino, S. Lalezari +3 more
2020European Journal of Haematology4 citations Open access
Semantic Scholar
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
M. Reding, I. Pabinger, P. Holme, Monika Maas Enriquez +6 more
2023Therapeutic Advances in Hematology3 citations Open access
Semantic Scholar
Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study
J. Ducore, S. Lalezari, E. Santagostino, S. Ahuja +3 more
2019Blood2 citations Open access
Semantic Scholar
Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension
M. Reding, S. Lalezari, I. Pabinger, Monica Maas Enriquez +1 more
2018Blood2 citations
Semantic Scholar
The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease
A. Barg, G. Kenet, T. Livnat, E. Avishai +8 more
20201 citations Open access
Semantic Scholar
Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
S. Lalezari, M. Acquadro, É. de Bock, J. Lambert +1 more
2020Advances in Therapy1 citations Open access
Semantic Scholar
Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension
M. Simpson, S. Ahuja, D. Tseneklidou-Stoeter, S. Lalezari
2018Blood1 citations
Semantic Scholar
Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study
T. Humphries, N. Church, S. Lalezari, L. Poulsen +2 more
20161 citations
Semantic Scholar
pharmacokinetics of Bay 94-9027, a Pegylated B-domain-deleted recombinant factor Viii with an extended half-life, in children, adolescents, and adults with severe hemophilia A
Anita Shah, T. Coyle, S. Lalezari, B. Kohlstaedde +3 more
20161 citations
Semantic Scholar
Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis
S. Lalezari, Rivka Carmiel, Ivan Budnik, G. Kenet +1 more
2023Blood0 citations Open access
Semantic Scholar
Neonatal circumcision in patients with haemophilia is safe – a single centre experience
A. Barg, Sarina Levy Mendelovich, S. Lalezari, S. Aviv +2 more
20170 citations Open access
Semantic Scholar
Impact of ethnic background and methylenetetrahydrofolate reductase genotype on age at onset of coronary artery disease among women in Israel
A. Mager, N. Koren-Morag, M. Shohat, S. Lalezari +2 more
20060 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Kenet×12
Invite
G. Kenet — researcher profile on SciRah
M. Reding×9
Invite
M. Reding — researcher profile on SciRah
A. Barg×7
Invite
A. Barg — researcher profile on SciRah
D. Tseneklidou-Stoeter×6
Invite
D. Tseneklidou-Stoeter — researcher profile on SciRah

×6

Invite

D. Bashari — researcher profile on SciRah

Invite

E. Avishai — researcher profile on SciRah

E. Santagostino×6

Invite

E. Santagostino — researcher profile on SciRah

Invite

M. Enriquez — researcher profile on SciRah

Invite

R. Dardik — researcher profile on SciRah

Invite

I. Pabinger — researcher profile on SciRah

Invite

L. Poulsen — researcher profile on SciRah

Invite

A. Lubetsky — researcher profile on SciRah